Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • GERALD
    Member
    • Jun 2010
    • 20

    #1

    Dragen

    When I first heard about Dragen, it sounded interesting but recently Edico has started to make this platform available on AWS, as well as several Bioinformatics-as-a-service platforms, including DNANexus, Seven Bridges and Illumina's BaseSpace:


    I think we should all be taking a hard look at this for a couple of reasons:
    • These platforms bring it to a wide audience and make it user-friendly
    • Platform effects: It's a hardware platform with inherent limits on configurability. This will tend to drive users to stadardize on it and effectively freeze pipelines to this standard.
    • It's not available on all platforms.
    • It's really fast!


    Based on this, I think it's something to discuss because it's going to have a big impact on the industry.
  • colindaven
    Senior Member
    • Oct 2008
    • 417

    #2
    You forgot the main arguments against DRAGEN

    -licenses are limited by throughput
    -licenses are REALLY expensive
    -licenses are limited by application (buy DNA-seq, can't do RNA-seq).

    Comment

    • NadiaEira
      Junior Member
      • Jan 2026
      • 1

      #3
      This will likely encourage users to conform to this standard and effectively halt any changes to pipelines that adhere to it.
      slope rider

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
        by SEQadmin2



        Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

        Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
        ...
        10-14-2026, 09:55 AM
      • SEQadmin2
        New Genomics Technologies Take Aim at Long-Standing Limits
        by SEQadmin2


        Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

        We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
        ...
        09-28-2026, 10:25 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, Yesterday, 10:52 AM
      0 responses
      9 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-14-2026, 05:39 AM
      0 responses
      19 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-13-2026, 09:56 AM
      0 responses
      16 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-09-2026, 11:14 AM
      0 responses
      27 views
      0 reactions
      Last Post SEQadmin2  
      Working...